Paul Schellhammer

722 total citations
23 papers, 530 citations indexed

About

Paul Schellhammer is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Urology. According to data from OpenAlex, Paul Schellhammer has authored 23 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 4 papers in Surgery and 4 papers in Urology. Recurrent topics in Paul Schellhammer's work include Prostate Cancer Diagnosis and Treatment (13 papers), Prostate Cancer Treatment and Research (10 papers) and Urinary Bladder and Prostate Research (4 papers). Paul Schellhammer is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (13 papers), Prostate Cancer Treatment and Research (10 papers) and Urinary Bladder and Prostate Research (4 papers). Paul Schellhammer collaborates with scholars based in United States, Canada and India. Paul Schellhammer's co-authors include Laurence Klotz, Kevin Carroll, Steven M. Schlossberg, Michael S. Cookson, Thomas M. Wheeler, Marc A. Bjurlin, Samir S. Taneja, Dean A. Troyer, H. Ballentine Carter and Leonard G. Gomella and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Quality of Life Research.

In The Last Decade

Paul Schellhammer

23 papers receiving 512 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Schellhammer United States 12 410 96 77 67 62 23 530
Edward P. DeAntoni United States 15 442 1.1× 54 0.6× 123 1.6× 97 1.4× 55 0.9× 23 643
Prasad Bollina United Kingdom 11 231 0.6× 91 0.9× 46 0.6× 74 1.1× 48 0.8× 18 496
Rikiya Taoka Japan 13 256 0.6× 41 0.4× 55 0.7× 182 2.7× 106 1.7× 64 557
J Bruin Rugge United States 5 302 0.7× 110 1.1× 36 0.5× 81 1.2× 13 0.2× 10 588
L. Brureau France 15 342 0.8× 34 0.4× 52 0.7× 93 1.4× 19 0.3× 55 535
Walsh Pc United States 10 291 0.7× 48 0.5× 69 0.9× 78 1.2× 54 0.9× 23 361
A. Zlotta Belgium 7 461 1.1× 44 0.5× 160 2.1× 65 1.0× 49 0.8× 20 553
Kris E. Gaston United States 12 285 0.7× 50 0.5× 42 0.5× 225 3.4× 79 1.3× 44 573
James L. Bailen United States 11 312 0.8× 161 1.7× 45 0.6× 67 1.0× 66 1.1× 41 518
Leslie Moffat United Kingdom 12 154 0.4× 24 0.3× 59 0.8× 116 1.7× 43 0.7× 24 449

Countries citing papers authored by Paul Schellhammer

Since Specialization
Citations

This map shows the geographic impact of Paul Schellhammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Schellhammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Schellhammer more than expected).

Fields of papers citing papers by Paul Schellhammer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Schellhammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Schellhammer. The network helps show where Paul Schellhammer may publish in the future.

Co-authorship network of co-authors of Paul Schellhammer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Schellhammer. A scholar is included among the top collaborators of Paul Schellhammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Schellhammer. Paul Schellhammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wojno, Kirk J., et al.. (2014). The Clinical and Economic Implications of Specimen Provenance Complications in Diagnostic Prostate Biopsies. The Journal of Urology. 193(4). 1170–1177. 6 indexed citations
2.
Bjurlin, Marc A., H. Ballentine Carter, Paul Schellhammer, et al.. (2013). Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen Processing. The Journal of Urology. 189(6). 2039–2046. 166 indexed citations
3.
Wilt, Timothy J, Roderick MacDonald, Karen L. Hagerty, et al.. (2010). 5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. British Journal of Urology. 106(10). 1444–1451. 29 indexed citations
4.
5.
Beydoun, Hind A., et al.. (2010). Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. British Journal of Urology. 106(3). 334–341. 9 indexed citations
6.
Kramer, Barnett S., Karen L. Hagerty, Stewart Justman, et al.. (2009). Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. The Journal of Urology. 181(4). 1642–1657. 37 indexed citations
7.
Kramer, Barnett S., Karen L. Hagerty, Stewart Justman, et al.. (2009). Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. Journal of Clinical Oncology. 27(9). 1502–1516. 71 indexed citations
8.
Klotz, Laurence & Paul Schellhammer. (2005). Combined Androgen Blockade: The Case for Bicalutamide. PubMed. 3(4). 215–219. 25 indexed citations
9.
Klotz, Laurence, Paul Schellhammer, & Kevin Carroll. (2004). A re‐assessment of the role of combined androgen blockade for advanced prostate cancer. British Journal of Urology. 93(9). 1177–1182. 61 indexed citations
10.
Forman, J.D., W. Robert Lee, Carlos A. Perez, et al.. (2000). Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.. PubMed. 215 Suppl. 1373–82. 4 indexed citations
11.
Pollack, Alan, S B Paryani, Cherie Perez, et al.. (2000). Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria.. PubMed. 215 Suppl. 1401–12. 3 indexed citations
12.
Roach, Mack, Carlos A. Perez, J.D. Forman, et al.. (2000). Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria.. PubMed. 215 Suppl. 1441–8. 3 indexed citations
13.
Schellhammer, Paul. (1999). An update on bicalutamide in the treatment of prostate cancer. Expert Opinion on Investigational Drugs. 8(6). 849–860. 12 indexed citations
14.
Kondylis, Filippos I., et al.. (1999). OUTCOME AFTER INTRAVESICAL BCG IS NOT AFFECTED BY T1a/T1b SUBSTAGING. The Journal of Urology. 284–284. 1 indexed citations
15.
Narayan, Perinchery, John Trachtenberg, Herbert Lepor, et al.. (1996). A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. Urology. 47(4). 497–504. 19 indexed citations
16.
Schellhammer, Paul, et al.. (1995). Reply by the authors. Urology. 46(6). 899–901. 1 indexed citations
17.
18.
Brenner, David, et al.. (1989). Squamous cell carcinoma of bladder after successful intravesical therapy with bacillus calmette-guérin. Urology. 34(2). 93–95. 12 indexed citations
19.
Jordan, Gerald H., David S. Hartman, Leopold E. Ladaga, & Paul Schellhammer. (1986). Large renal masses in young adults. Urology. 28(4). 330–337. 2 indexed citations
20.
Zerhouni, Elias A., et al.. (1984). Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosis. Urologic Radiology. 6(1). 205–9. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward P. DeAntoni Breakdown of academic impact, for papers by Prasad Bollina Breakdown of academic impact, for papers by Rikiya Taoka Breakdown of academic impact, for papers by J Bruin Rugge Breakdown of academic impact, for papers by L. Brureau Breakdown of academic impact, for papers by Walsh Pc Breakdown of academic impact, for papers by A. Zlotta Breakdown of academic impact, for papers by Kris E. Gaston Breakdown of academic impact, for papers by James L. Bailen Breakdown of academic impact, for papers by Leslie Moffat
Rankless by CCL
2026